ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

In Brief: Treatment Reorganization Plan Due In November, Rauscher Says; Panel To Review Clinical Activities

June 27, 1975

Letters: NCI Mammography Statement Recognizes Patient Autonomy

February 25, 1994

NCI Seeks Prevention Fellows.

March 9, 2001

Phase III Regorafenib Trial Meets PFS Primary Endpoint

June 29, 2012

DePinho’s Wife Was Briefed on AVEO Data 11 Days Before He Touted Stock on CNBC

September 13, 2013

DePinho’s Handling Of MD Anderson Tenure Dispute Triggers Formal Investigation by AAUP

July 18, 2014